Arcellx (ACLX) Competitors

Arcellx (NASDAQ:ACLX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Is ACLX or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Arcellx's net margin of -25.94%. Genmab A/S's return on equity of 16.78% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-25.94%	-8.28%	-5.21%
Genmab A/S	36.30%	16.78%	13.79%

Do insiders and institutionals hold more shares of ACLX or GMAB?

96.0% of Arcellx shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 6.2% of Arcellx shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer ACLX or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Arcellx. MarketBeat recorded 21 mentions for Genmab A/S and 20 mentions for Arcellx. Arcellx's average media sentiment score of 1.04 beat Genmab A/S's score of 0.70 indicating that Arcellx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcellx	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	9 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ACLX or GMAB?

Arcellx has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Does the MarketBeat Community favor ACLX or GMAB?

Genmab A/S received 98 more outperform votes than Arcellx when rated by MarketBeat users. However, 83.13% of users gave Arcellx an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Arcellx	Outperform Votes 69 83.13%	Underperform Votes 14 16.87%
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%

Do analysts rate ACLX or GMAB?

Arcellx presently has a consensus target price of $111.33, indicating a potential upside of 83.90%. Genmab A/S has a consensus target price of $39.17, indicating a potential upside of 92.65%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Which has preferable valuation and earnings, ACLX or GMAB?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$76.81M	43.43	-$70.69M	-$2.99	-20.25
Genmab A/S	$3.12B	4.18	$1.14B	$1.76	11.55

Summary

Genmab A/S beats Arcellx on 11 of the 18 factors compared between the two stocks.